NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
Clinical Trials
141 trialsNCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT04701918 2026-01-22
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT05512377 2026-01-21
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Completed
NCT02625961 2025-11-21
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03914794 2025-10-03
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02553642 2025-07-22
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02015104 2025-07-01
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02662309 2025-03-10
ABACUS
Queen Mary University of London
Phase 2 Completed
NCT00627432 2025-02-18
Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT01489813 2025-02-05
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Emory University
Phase 2 Completed
NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT04576286 2025-01-28
Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder
Ain Shams University
Phase 2 Completed
NCT02662062 2025-01-27
PCR-MIB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03534804 2024-11-26
PemCab
University of Utah
Phase 2 Completed
NCT00981656 2024-09-19
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02177695 2024-09-19
COXEN
SWOG Cancer Research Network
Phase 2 Completed
NCT04593862 2024-09-19
BRAVE
University of Alberta
Phase 2 Completed
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT03513952 2024-07-26
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT03558087 2024-06-27
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Hoosier Cancer Research Network
Phase 2 Completed
NCT03319745 2024-06-25
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04525131 2024-06-18
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
CicloMed LLC
Phase 2 Completed
NCT02108652 2024-03-28
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Hoffmann-La Roche
Phase 2 Completed
NCT02951767 2024-03-28
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
Hoffmann-La Roche
Phase 2 Completed
NCT04496219 2024-01-02
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00002914 2023-06-22
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003129 2023-06-22
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00005644 2023-06-22
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01684098 2023-06-22
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Endocyte
Phase 2 Completed
NCT04311580 2023-06-22
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
University of Rome Tor Vergata
Phase 2 Completed
NCT00004223 2023-06-18
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT04209192 2023-04-04
Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Completed
NCT02335424 2023-03-02
MK-3475-052
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02281383 2023-02-08
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03058757 2023-01-31
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation
National Cancer Center, Korea
Phase 2 Completed
NCT03212651 2023-01-20
PANDORE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT00805129 2022-11-25
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03980041 2022-11-25
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT02500121 2022-09-30
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01780545 2022-07-11
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00777491 2022-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT03628716 2022-04-27
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bavarian Nordic
Phase 2 Completed
NCT00710970 2022-01-24
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Baylor College of Medicine
Phase 2 Completed